Study Finds Effective Methods for Smoking Cessation

Aug.30.2022
Study Finds Effective Methods for Smoking Cessation
A study found that varenicline, bupropion, and low-dose e-cigarettes were the most effective smoking cessation methods.

A study titled "Pharmacological and e-cigarette intervention for smoking cessation: systematic review, network meta-analysis, and cost-effectiveness analysis" was conducted by researchers at the University of Bristol in the UK. They searched a publication database up to March 2017 and updated their search in February 2019 with randomized clinical trials of smoking cessation interventions lasting for over six months.


The research team ultimately conducted a total of 363 experiments involving 201,045 participants. Additionally, they conducted 53 observational studies, which involved 8,783,5403 participants for safety review purposes.


After analyzing the results, the research team has concluded that the most effective treatment methods are substituting with Varencicline Standard plus Nicotine (odds ratio [OR], 3.22; 95% credible interval [CrI], 2.27-14.88), substituting with Varenicline Low plus Nicotine (OR, 5.70; 95% CrI, 1.57-21.12), and using low electronic cigarettes (OR, 3.22; 95% CrI, 0.97-12.55).


A controversial drug.


On October 1, 2021, the drug varenicline, commonly sold under the name Champix, was added to the World Health Organization's Essential Medicines List. This anti-smoking medication is well-known for helping smokers overcome cravings for cigarettes. However, despite being considered highly effective, it can also cause moderate to severe psychological side effects, ranging from terrifying nightmares to suicidal thoughts.


After multiple reports of such disturbances, the US Food and Drug Administration (FDA) issued the most severe warning for the drug, causing the sales of Valeni-cline to decrease from $846 million in 2008 to $671 million last year.


In order to overcome this decline, Pfizer, the manufacturer of the drug, has invested heavily in advertising and resolving lawsuits related to the medication. Additionally, the pharmaceutical company has released data retrieved from a study that allegedly proves that consuming Valenicline does not have a direct link to experiencing psychological disorders.


Subsequently, after refusing to lift the warning in 2014, the FDA recently decided to change their stance and abandon the warning. The agency has requested the listing of side effects associated with the drug, and has established a requirement that the label specify that varenicline is more effective than other smoking cessation therapies.


Vonnicron stock recall


Meanwhile, in June of last year, Pfizer was forced to halt distribution of Valsartan after discovering increased levels of nitrosamine in the pills and recalled some of its stock. However, in the following month, the US Food and Drug Administration announced that it would temporarily allow some manufacturers to distribute drugs containing carcinogens below a temporary limit of 185 nanograms per day until impurities could be eliminated or reduced to acceptable levels.


Disclaimer: 1. The content of this article is compiled from third-party information and is only intended for industry exchange and learning purposes. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The compilation of this article is only intended for industry exchange and research. 3. Due to the limitations of the compilation level, the compiled article may not express the same meaning as the original article. Please refer to the original article for accuracy. 4. For any domestic, Hong Kong, Macao, Taiwan, and foreign statements and positions, 2FIRSTS fully aligns with the Chinese government. 5. The copyright of the information compiled belongs to the original media and author. If there is any infringement, please contact us to delete it.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
HM Revenue & Customs put the UK's Vaping Products Duty and Vaping Duty Stamps Scheme into effect on October 1. All vaping liquids manufactured in or imported into the UK are now subject to duty at £2.20 per 10ml, regardless of nicotine content. The stamp regime will introduce digital functionality designed to provide traceability throughout the supply chain, with approved manufacturers, importers and warehousekeepers required to report product movements and retailers and consumers eventually able to scan stamps to verify authenticity. China exported $177 million of vape-related products to the UK in August, up 51.4% year over year, increasing the significance of the new compliance regime for China's Shenzhen-centered vape supply chain.
Regulations
Oct.04
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
After more than 30 years researching tobacco harm reduction, University of Louisville professor Brad Rodu says opposition to smoke-free alternatives still surprises him. In an exclusive 2Firsts interview in Manila, he argued that declining smoking rates represent progress even if nicotine use rises, discussed nicotine and cancer, and examined Sweden's snus experience and youth vaping. Rodu welcomed recent FDA decisions but criticized slow reviews and poor risk communication. He called a change in the WHO's stance potentially significant, while doubting it would happen soon.
Nov.20
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's Four-Year Tobacco Tax Plan Heads to Parliament as BAT, JTI and PMI Push for Changes
Germany's parliament is scheduled to hold a first reading of amendments to the Tobacco Tax Act on September 24. The government plans annual tax increases from 2027 through 2030 covering cigarettes, heated tobacco, vaping liquids and other categories. It expects the reform to generate €756 million in additional revenue in 2027, rising to €3.589 billion in additional annual revenue by 2030. Ahead of the parliamentary debate, the German Association of the Tobacco Industry and Novel Products, or BVTE, launched the "Tabaksteuer mit Augenmaß" campaign backed by BAT, JTI, Philip Morris, Reemtsma and wholesale and retail groups.
Sep.23
Italy Proposes Earlier Vape and HTP Tax Hikes, New Rules for E-Liquid Pricing, Exclusive Deals and Distribution
Italy Proposes Earlier Vape and HTP Tax Hikes, New Rules for E-Liquid Pricing, Exclusive Deals and Distribution
Italy's proposed 2027–2029 budget would bring forward scheduled tax increases for e-cigarette liquids and heated tobacco products from January 1, 2028, to July 1, 2027. The consumption tax coefficient for nicotine-containing e-liquids would rise from 20% to 22%, that for nicotine-free liquids and applicable flavorings from 15% to 17%, and the heated-tobacco coefficient from 41% to 42%. The bill would also introduce official retail price schedules for e-liquids, restrict exclusive agreements between retailers and suppliers, and limit single-brand-dominated displays, sales incentives and bundled offers. Importing, authorized warehousing and retailer sourcing arrangements would also change. The proposals remain subject to parliamentary approval and subsequent implementing regulations.
Regulations
Nov.04
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Kelly White Bets on Female Consumers as Nicotine Pouch Competition Intensifies | 2Firsts Interview
Swedish nicotine pouch brand Kelly White is building its strategy around adult female consumers. Founder and CEO Sophia Wilsby told 2Firsts that women accounted for around 70% of the brand’s repeat customers on HAYPP in Sweden in 2025. The interview explores female consumer segmentation, product and design differentiation, gender stereotypes, packaging regulation, and how independent brands can compete with global players such as ZYN and VELO while considering funding, partnerships and future ownership options.
Business
Sep.24